BioLine RX Ltd
BLRX3.550USD
-0.080-2.20%
Close 09/04, 16:00（ET）Quotes delayed by 15 min
9.08BMarket Cap
LossP/E TTM
More Details of BioLine RX Ltd Company
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Company Info
Ticker SymbolBLRX
Company nameBioLine RX Ltd
IPO dateJan 30, 2007
CEOMr. Philip Adam (Phil) Serlin
Number of employees28
Security typeOrdinary Share
Fiscal year-endJan 30
AddressModi'in Technology Park
CityMODIIN
Stock exchangeTel Aviv Stock Exchange
CountryIsrael
Postal code7177871
Phone97286429100
Websitehttps://www.biolinerx.com/
Ticker SymbolBLRX
IPO dateJan 30, 2007
CEOMr. Philip Adam (Phil) Serlin
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Hillit Mannor Shachar
Dr. Hillit Mannor Shachar
Vice President - Business Development
Vice President - Business Development
--
--
Dr. Sandra Panem, Ph.D.
Dr. Sandra Panem, Ph.D.
Director
Director
--
--
Mr. Philip Adam (Phil) Serlin
Mr. Philip Adam (Phil) Serlin
Chief Executive Officer
Chief Executive Officer
--
--
Dr. Michael J. Anghel
Dr. Michael J. Anghel
Director
Director
--
--
Dr. Ella Sorani
Dr. Ella Sorani
Vice President - Development
Vice President - Development
--
--
Dr. Barbara-Jean (BJ) Bormann
Dr. Barbara-Jean (BJ) Bormann
Director
Director
--
--
Mr. Gal Cohen
Mr. Gal Cohen
Independent Director
Independent Director
--
--
Ms. Nurit Benjamini
Ms. Nurit Benjamini
External Director
External Director
--
--
Ms. Mali Zeevi
Ms. Mali Zeevi
Chief Financial Officer
Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Hillit Mannor Shachar
Dr. Hillit Mannor Shachar
Vice President - Business Development
Vice President - Business Development
--
--
Dr. Sandra Panem, Ph.D.
Dr. Sandra Panem, Ph.D.
Director
Director
--
--
Mr. Philip Adam (Phil) Serlin
Mr. Philip Adam (Phil) Serlin
Chief Executive Officer
Chief Executive Officer
--
--
Dr. Michael J. Anghel
Dr. Michael J. Anghel
Director
Director
--
--
Dr. Ella Sorani
Dr. Ella Sorani
Vice President - Development
Vice President - Development
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Hong Seng Technology Ltd
4.01%
Citadel Advisors LLC
0.35%
Simplex Trading, LLC
0.33%
Two Sigma Investments, LP
0.32%
Susquehanna International Group, LLP
0.26%
Other
94.73%
Shareholders
Shareholders
Proportion
Hong Seng Technology Ltd
4.01%
Citadel Advisors LLC
0.35%
Simplex Trading, LLC
0.33%
Two Sigma Investments, LP
0.32%
Susquehanna International Group, LLP
0.26%
Other
94.73%
Shareholder Types
Shareholders
Proportion
Corporation
4.08%
Hedge Fund
0.67%
Research Firm
0.48%
Investment Advisor
0.39%
Other
94.37%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
62
197.43K
4.63%
-93.51K
2025Q1
65
183.31K
4.30%
-165.57K
2024Q4
63
222.04K
6.08%
+67.69K
2024Q3
62
233.17K
7.79%
-25.85K
2024Q2
66
277.79K
10.04%
+89.80K
2024Q1
64
205.72K
6.62%
+27.03K
2023Q4
67
200.88K
6.35%
-8.70K
2023Q3
69
34.99K
2.17%
-169.90K
2023Q2
63
31.93K
2.08%
-207.57K
2023Q1
65
80.66K
5.25%
-259.21K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Hong Seng Technology Ltd
170.73K
4.01%
--
--
Mar 16, 2025
Simplex Trading, LLC
--
0%
-50.00
-100.00%
Jun 30, 2024
Rhumbline Advisers Ltd. Partnership
1.53K
0.04%
+456.00
+42.46%
Mar 31, 2025
Intracoastal Capital, L.L.C.
3.13K
0.07%
+3.13K
--
Mar 16, 2025
Wells Fargo Advisors
3.00K
0.07%
+2.86K
+2073.91%
Mar 31, 2025
Morgan Stanley Smith Barney LLC
900.00
0.02%
+900.00
--
Mar 31, 2025
View more
Related ETFs
Updated: Wed, Aug 6
Updated: Wed, Aug 6
Name
Proportion
ActivePassive International Equity ETF
0%
ActivePassive International Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 17, 2025
Merger
40→1
Jan 17, 2025
Merger
40→1
Jan 17, 2025
Merger
40→1
Jan 17, 2025
Merger
40→1
Date
Type
Ratio
Jan 17, 2025
Merger
40→1
Jan 17, 2025
Merger
40→1
Jan 17, 2025
Merger
40→1
Jan 17, 2025
Merger
40→1
